Triple
T17377641
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Horizon Discovery |
E422481
|
entity |
| Predicate | technology |
P1485
|
FINISHED |
| Object | CRISPR-Cas9 |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CRISPR-Cas9 | Statement: [Horizon Discovery, technology, CRISPR-Cas9]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CRISPR-Cas9 Context triple: [Horizon Discovery, technology, CRISPR-Cas9]
-
A.
CRISPR-Cas9 gene-editing technology
chosen
CRISPR-Cas9 gene-editing technology is a revolutionary molecular tool that allows scientists to precisely modify DNA within living organisms, transforming research, medicine, and biotechnology.
-
B.
CRISPR-Cas systems
CRISPR-Cas systems are adaptive immune mechanisms found in bacteria and archaea that have been repurposed as powerful, programmable tools for genome editing and gene regulation.
-
C.
Cpf1 (Cas12a)
Cpf1 (Cas12a) is a CRISPR-associated endonuclease used for genome editing that recognizes different DNA target sequences and creates staggered cuts, offering distinct advantages and applications compared to Cas9.
-
D.
SaCas9
SaCas9 is a compact Cas9 nuclease derived from Staphylococcus aureus that enables CRISPR-based genome editing, particularly useful where smaller delivery vectors such as AAV are required.
-
E.
CRISPR Therapeutics
CRISPR Therapeutics is a biotechnology company focused on developing gene-editing therapies using CRISPR/Cas9 technology to treat serious diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d889d6535c81908be333c01deaec4e |
completed | April 10, 2026, 5:25 a.m. |
| NER | Named-entity recognition | batch_69e43a6ea56c8190b56d966ccf2c91f7 |
completed | April 19, 2026, 2:14 a.m. |
Created at: April 10, 2026, 5:45 a.m.